SANGAMO THERAPEUTICS, INC 8-K

What Happened
Sangamo Therapeutics, Inc. (SGMO) reported that Nasdaq's Listing Qualifications Staff issued a Delisting Notice on April 28, 2026, determining to delist the company's common stock for failure to meet the $1.00 minimum bid price requirement. Nasdaq will suspend trading in SGMO on The Nasdaq Capital Market at the open on May 5, 2026. The company plans to request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination; a timely hearing request will delay the delisting process but will not prevent the trading suspension.

Key Details

• Initial noncompliance notice: April 30, 2025 — closing bid below $1.00 for 30 consecutive business days.
• First compliance deadline: October 27, 2025; later granted an additional 180-day extension to April 27, 2026.
• Delisting Notice received: April 28, 2026; trading suspension effective at open May 5, 2026.
• OTCQB approval: SGMO approved to be quoted on the OTCQB Venture Market and expects OTCQB trading to commence May 5, 2026 under ticker "SGMO."
• Filing signed by Scott B. Willoughby, Chief Legal Officer and Corporate Secretary (dated April 29, 2026).

Why It Matters

• Liquidity and visibility: Suspension from Nasdaq reduces visibility and may lower liquidity for shareholders; quotation on OTCQB provides an alternate trading venue but is generally less liquid and less regulated than Nasdaq.
• Procedural status: The company is appealing the delisting decision; however, the appeal does not prevent the immediate trading suspension, so Nasdaq trading will remain halted unless the Hearings Panel orders reinstatement.
• Investor action: Shareholders should be aware of the trading venue change, possible wider bid-ask spreads, and follow future company and Nasdaq updates for the outcome of the hearing and any changes to trading status.